Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
12:31:46 EDT Wed 01 May 2024
Enter Symbol
or Name
USA
CA



Q:NURO - NEUROMETRIX INC - https://www.neurometrix.com/
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
NURO - Q0.54.21·4.350.14.35-0.02-0.53.012244.3501  4.52  4.3511.52  2.7012:12:51Apr 1915 min RT 2¢

Recent Trades - Last 10 of 24
Time ETExPriceChangeVolume
12:12:51Q4.37 400
12:12:51Q4.37 105
12:12:51Q4.36-0.011
12:12:51Q4.35-0.02100
12:12:51Q4.2828-0.08721
12:02:02Q4.37 83
11:38:43Q4.3950.0251
10:59:49Q4.3950.0258
10:58:37Q4.37 101
10:58:37Q4.37 100

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2024-04-19 08:00U:NURONews ReleaseNeuroMetrix Announces Steps Taken to Enhance Shareholder Value
2024-03-14 09:00U:NURONews ReleaseNeuroMetrix Announces Publication of Study Demonstrating that DPNCheck Accurately Diagnoses Diabetic Peripheral Neuropathy
2024-03-13 09:00U:NURONews ReleaseNeuroMetrix announces that over 2000 patients with fibromyalgia have been prescribed Quell(TM) Fibromyalgia
2024-03-12 08:04U:NURONews ReleaseEcho Lake Capital Issues Top Ten List of Reasons Why Shai Gozani, CEO of Neurometrix Inc., Should Be Fired
2024-03-04 08:06U:NURONews ReleaseEcho Lake Capital Calls for the Liquidation of Neurometrix, Inc.
2024-02-22 07:00U:NURONews ReleaseNeuroMetrix Reports Q4 and Full Year 2023 Business Highlights
2024-02-15 09:00U:NURONews ReleaseNeuroMetrix, Inc. Announces Date for Fourth Quarter and Full Year 2023 Business Highlights Conference Call
2024-02-13 09:00U:NURONews ReleaseNeuroMetrix Announces Review of Strategic Options to Promote Growth and Maximize Shareholder Value
2024-01-08 09:43U:NURONews ReleaseNeuroMetrix to Present at the Emerging Growth Conference on January 10, 2024
2023-12-12 09:00U:NURONews ReleaseNeuroMetrix Reports Encouraging Results from Pilot Clinical Trial of Quell ‚ ® in Post-Acute COVID-19 Syndrome (Long COVID)
2023-12-05 09:00U:NURONews ReleaseNeuroMetrix Announces Peer-Reviewed Publication of Phase 2 Clinical Trial Showing that Quell ‚ ® Improves Painful Symptoms of Chemotherapy Induced Peripheral Neuropathy (CIPN)
2023-11-20 09:00U:NURONews ReleaseNeuroMetrix Announces One-for-Eight Reverse Stock Split
2023-10-26 07:00U:NURONews ReleaseNeuroMetrix Reports Q3 2023 Business Highlights
2023-10-23 11:14U:NURONews ReleaseNeuroMetrix, Inc. Announces Date for Third Quarter 2023 Business and Financial Highlights Conference Call
2023-10-02 09:00U:NURONews ReleaseNeuroMetrix and the National Fibromyalgia Association to Collaborate to Improve the Quality of Life for People Living with Fibromyalgia
2023-07-27 07:00U:NURONews ReleaseNeuroMetrix Reports Q2 2023 Business Highlights
2023-07-20 13:00U:NURONews ReleaseNeuroMetrix, Inc. Announces Date for Second Quarter 2023 Business and Financial Highlights Conference Call
2023-07-11 09:00U:NURONews ReleaseNeuroMetrix Announces Sales Force Expansion for Quell Fibromyalgia
2023-06-28 09:00U:NURONews ReleaseRecent Publications Demonstrate Utility of DPNCheck ‚ ® for Identifying High-Risk Diabetes Patients
2023-06-07 09:00U:NURONews ReleaseDiabetic Peripheral Neuropathy Screening That Includes DPNCheck ‚ ® Predicts Mortality In A Prospective Clinical Study